Larry Skelton
Moundville, ALNPI 1245207448
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.
Across 238 payments — averaging $14.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$750
- Novo Nordisk$576
- Lilly USA, LLC$333
- Pfizer$235
- AstraZeneca$186
- Novartis$185
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,29397%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 81 | $750 |
| Novo Nordisk | 48 | $576 |
| Lilly USA, LLC | 16 | $333 |
| Pfizer | 14 | $235 |
| AstraZeneca | 6 | $186 |
| Novartis | 13 | $185 |
| Johnson & Johnson | 7 | $139 |
| Daiichi Sankyo Inc. | 7 | $121 |
| Merck | 6 | $103 |
| Astellas Pharma US Inc | 1 | $94 |
| Amgen | 6 | $94 |
| Boehringer Ingelheim | 5 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| GSK | 4 | $54 |
| Ultragenyx Pharmaceutical Inc. | 2 | $47 |
| Dexcom, Inc. | 2 | $44 |
| Azurity Pharmaceuticals, Inc. | 1 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Athena Bioscience, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$117
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $11,370 |
| TradjentaLinagliptin | 13 | $6,839 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,936 |
| Rosuvastatin Calcium | 61 | $1,078 |
| Famotidine | 28 | $870 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $780 |
| Pravastatin Sodium | 42 | $750 |
| Atorvastatin Calcium | 39 | $631 |
| Buspirone Hcl | 34 | $555 |
| Metformin Hcl | 46 | $539 |
| Amlodipine Besylate | 48 | $531 |
| Levothyroxine Sodium | 38 | $505 |
| Tamsulosin Hcl | 23 | $439 |
| Losartan Potassium | 29 | $439 |
| Potassium Chloride | 34 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $235 | $11,37017 claims |
| Boehringer IngelheimTradjenta | $78 | $6,83913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.